Does CRISPR-Cas open new possibilities for patents or present a moral maze?

CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2014-04, Vol.32 (4), p.331-333
Main Author: Webber, Philip
Format: Article
Language:English
Subjects:
631/154/2426/1984
706/648/179
706/703/270
Agriculture
Animals
Animals, Genetically Modified
Appreciation
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Biotechnology - ethics
Biotechnology - legislation & jurisprudence
Clustered Regularly Interspaced Short Palindromic Repeats
CRISPR-Cas Systems
Enzymes
Forecasts and trends
Genes
Life Sciences
Medical ethics
Patent licenses
Patents as Topic - ethics
Patents as Topic - legislation & jurisprudence
Proteins
Transgenic plants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.2843